AOC-1001 is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase II program in Myotonic Dystrophy. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of AOC-1001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for AOC-1001 is expected to reach an annual total of $5 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
AOC-1001 is under development for the treatment of myotonic dystrophy type 1. It is administered through intravenous route. The drug candidate is an antibody oligonucleotide conjugate (AOC), containing mAb that targets cells expressing transferrin receptor 1 (TfR1) to deliver an siRNA targeting the mRNA encoding DMPK.
Avidity Biosciences Overview
Avidity Biosciences, formerly Avidity NanoMedicines is a biotech company that develops antibody oligonucleotide conjugates (AOCs). Its proprietary platform technology has enhanced pharmacokinetic and biodistribution properties that improve the delivery of multiple therapeutic oligonucleotides. Its pipeline of therapeutic programs is intended for the treatment of rare muscle disorders and other serious diseases, including Duchenne muscular dystrophy, myotonic dystrophy and muscle atrophy. The company has research collaborations with leading pharma companies, to discover antibody-based drug candidates against various therapeutic targets. Avidity Biosciences is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$9.2 million for the fiscal year ended December 2022 (FY2022), a decrease of 1.1% over FY2021. The operating loss of the company was US$178.9 million in FY2022, compared to an operating loss of US$118.1 million in FY2021. The net loss of the company was US$174 million in FY2022, compared to a net loss of US$118 million in FY2021.
For a complete picture of AOC-1001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.